

NCT02965027 comparison:

Summary:
CHIA has 37 criteria while your personal folder has 37 criteria
Total found criteria: 31/37
Total not Found: 6/37
Total Extra: 11
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male and female Active-duty SMs or Veterans aged   │ Male and female Active-duty Servicemembers (SMs)   │
│ 18 or older who are in good general health         │ or Veterans aged 18 or older who are in good       │
│                                                    │ general health                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential must agree to      │ Participants of childbearing potential must agree  │
│ abstain from sexual relations that could result in │ to abstain from sexual relations that could result │
│ pregnancy or use an effective method of birth      │ in pregnancy or use an effective method of birth   │
│ control acceptable to both participant and the     │ control acceptable to both participant and the     │
│ clinician prescriber during the study. Men are not │ clinician prescriber during the study.             │
│ required to use contraception during the study     │ Participants who are not of childbearing potential │
│                                                    │ are not required to use contraception during the   │
│                                                    │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participants must have English fluency sufficient  │ Participants must have English fluency sufficient  │
│ to complete study measures                         │ to complete study measures                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in other interventional research     │ Participation in other interventional research     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of penetrating head injury                 │ History of penetrating head injury                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of TBI more severe than mild by DVBIC      │ History of TBI more severe than mild by DVBIC      │
│ criteria                                           │ criteria                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HAs of any kind of moderate or severe intensity on │ HAs of any kind of moderate or severe intensity on │
│ an average of more than 2 days per month preceding │ an average of more than 4 days per month preceding │
│ the concussive trauma                              │ the concussive trauma                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute or serious medical illness or unstable       │ Acute or serious medical illness or unstable       │
│ chronic medical illness (e.g., unstable angina,    │ chronic medical illness (e.g., unstable angina,    │
│ myocardial infarction within 6 months, congestive  │ myocardial infarction within 6 months, congestive  │
│ heart failure, clinically significant or           │ heart failure, clinically significant or           │
│ concerning cardiac arrhythmias; preexisting        │ concerning cardiac arrhythmias; preexisting        │
│ hypotension [systolic blood pressure<110] or       │ hypotension \[systolic blood pressure\<110\] or    │
│ orthostatic hypotension [systolic drop >20 mm Hg   │ orthostatic hypotension \[systolic drop \>20 mm Hg │
│ after 2 min standing accompanied by                │ after 2 min standing accompanied by                │
│ lightheadedness], chronic renal or hepatic         │ lightheadedness\], chronic renal or hepatic        │
│ failure, acute pancreatitis, Meniere's disease, or │ failure, or acute pancreatitis. The eligibility of │
│ diagnosed but untreated sleep apnea). The          │ potential participants having acute serious and/or │
│ eligibility of potential participants having acute │ chronic medical illnesses other than those listed  │
│ serious and/or chronic medical illnesses other     │ will be evaluated on a case-by-case basis by a     │
│ than those listed will be evaluated on a case-by-  │ study physician, physician assistant - certified   │
│ case basis by a study physician, PA-C, or ARNP     │ (PA-C), or advanced registered nurse practitioner  │
│                                                    │ (ARNP)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of prazosin or other alpha-1 antagonist        │ Use of prazosin or other alpha-1 antagonist        │
│ (including but not limited to alfuzosin,           │ (including but not limited to alfuzosin,           │
│ doxazosin, silodosin, tamsulosin, terazosin) for   │ doxazosin, silodosin, tamsulosin, terazosin) for   │
│ any purpose in the 2 weeks prior to initial screen │ any purpose in the 2 weeks prior to initial screen │
│ (P1) visit and prohibited throughout the study     │ (P1) visit and prohibited throughout the study     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Allergy or previous adverse reaction to prazosin   │ Allergy or previous adverse reaction to prazosin   │
│ or other alpha-1 antagonist                        │ or other alpha-1 antagonist                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active psychosis or psychotic disorder, severe     │ Active psychosis or psychotic disorder, severe     │
│ depression (as determined per clinician prescriber │ depression (as determined per clinician prescriber │
│ judgment), severe psychiatric instability or       │ judgment), severe psychiatric instability or       │
│ severe situational life crisis (including evidence │ severe situational life crisis (including evidence │
│ of being actively suicidal or homicidal)           │ of being actively suicidal or homicidal)           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Meets Diagnostic and Statistical Manual of Mental  │ Meets Diagnostic and Statistical Manual of Mental  │
│ Disorders, 5th Edition (DSM-5) criteria for any    │ Disorders, 5th Edition (DSM-5) criteria for any    │
│ Substance Use Disorder except caffeine-related     │ Substance Use Disorder except caffeine-related     │
│ disorders, or tobacco-related disorders            │ disorders, or tobacco-related disorders            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of delirium within the prior 3 months,     │ History of delirium within the prior 3 months,     │
│ epilepsy, stroke, dementia, psychotic disorder, or │ epilepsy, stroke, dementia, psychotic disorder, or │
│ bipolar disorder                                   │ bipolar disorder                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Structural brain abnormalities on any prior        │ Structural brain abnormalities on any prior        │
│ imaging with associated clinically evident         │ imaging with associated clinically evident         │
│ manifestations                                     │ manifestations                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current participation in transcranial magnetic     │ Current participation in transcranial magnetic     │
│ stimulation studies                                │ stimulation studies                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential must not be        │ Women of childbearing potential must not be        │
│ pregnant, planning to become pregnant during the   │ pregnant, planning to become pregnant during the   │
│ study period, or nursing                           │ study period, or nursing                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in a HA support group or other       │ Participation in a HA support group or other       │
│ activity such as meditation or yoga intended to    │ activity such as meditation or yoga intended to    │
│ mitigate HA or other chronic pain must be stable   │ mitigate HA or other chronic pain must be stable   │
│ at least 4 weeks prior to beginning the initial    │ at least 4 weeks prior to beginning the initial    │
│ screen (P1) visit and may not be started during    │ screen (P1) visit and may not be started during    │
│ the study                                          │ the study                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Failure to record HA data for at least 80% of days │ Failure to record HA data for at least 80% of days │
│ during the Screening Period                        │ during the Screening Period                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Not suitable for study per clinician judgement     │ Not suitable for study per clinician judgement     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The use of HA rescue or symptom-relieving          │ The use of HA rescue or symptom-relieving          │
│ medications will be allowed during the study. This │ medications will be allowed during the study. This │
│ includes triptans, ergotamines, opioids, simple    │ includes triptans, ergotamines, opioids, simple    │
│ analgesics (e.g. acetaminophen, aspirin, or non-   │ analgesics (e.g. acetaminophen, aspirin, or non-   │
│ steroidal anti-inflammatories [NSAIDS], and        │ steroidal anti-inflammatories \[NSAIDS\], and      │
│ combination analgesics. Their use will be recorded │ combination analgesics. Their use will be recorded │
│ on the concurrent medication CRF during the        │ on the concurrent medication case report form      │
│ Preliminary Screening Period (P1) and throughout   │ (CRF) during the Preliminary Screening Period (P1) │
│ the remainder of the study. Randomization of       │ and throughout the remainder of the study.         │
│ participants will be stratified based on whether   │ Randomization of participants will be stratified   │
│ their use of HA medications meets ICHD-3 beta      │ based on whether their use of HA medications meets │
│ criteria for overuse of these medications, as      │ International Classification of Headache Disorders │
│ described in section 5.5 below                     │ 3rd addition (ICHD-3 beta) criteria for overuse of │
│                                                    │ these medications, as described in section 5.5     │
│                                                    │ below                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Opioid Medications: Use of opioids for treatment   │ Opioid Medications: Use of opioids for treatment   │
│ of HA or non-HA-related pain or for any other      │ of HA or non-HA-related pain or for any other      │
│ purpose is allowed during the study. Any opioid    │ purpose is allowed during the study. Any opioid    │
│ use would ideally be excluded due to potential     │ use would ideally be excluded due to potential     │
│ confounding effects on interpretation of response  │ confounding effects on interpretation of response  │
│ to treatment. However, in this population,         │ to treatment. However, in this population,         │
│ particularly in Veterans with chronic pain or      │ particularly in Veterans with chronic pain or      │
│ undergoing minor orthopedic or dental procedures,  │ undergoing minor orthopedic or dental procedures,  │
│ opioid use is common. Use of opioids, including    │ opioid use is common. Use of opioids, including    │
│ frequency and dose, will be recorded on the        │ frequency and dose, will be recorded on the        │
│ concurrent medication CRF                          │ concurrent medication CRF                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other Medications: Participants who are taking     │ Other Medications: Participants who are using      │
│ other medications on a routine basis must be on a  │ other medications or treatments on a routine basis │
│ stable dose for at least 4 weeks prior to the      │ must be on a stable dose for at least 4 weeks      │
│ Preliminary Screening Period (P1), and must intend │ prior to the Preliminary Screening Period (P1),    │
│ to continue the medication at the same regimen for │ and must intend to continue the medication at the  │
│ the duration of the trial unless lack of efficacy, │ same regimen for the duration of the trial unless  │
│ safety, or tolerability dictates otherwise. The    │ lack of efficacy, safety, or tolerability dictates │
│ following medications are not excluded             │ otherwise. The following medications and           │
│                                                    │ treatments are not excluded                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Psychoactive drugs (for example, anticonvulsants,  │ Psychoactive drugs (for example, anticonvulsants,  │
│ benzodiazepines, antidepressants,                  │ benzodiazepines, antidepressants,                  │
│ sedative/hypnotics)                                │ sedative/hypnotics)                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Antihypertensive medications (including beta-      │ Antihypertensive medications (including beta-      │
│ blockers, calcium channel blockers, angiotensin    │ blockers, calcium channel blockers, angiotensin    │
│ converting enzyme [ACE] inhibitors, and            │ converting enzyme \[ACE\] inhibitors, and          │
│ angiotensin receptor blockers)                     │ angiotensin receptor blockers)                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The use of magnesium in any dose that is           │ The use of magnesium in any dose that is           │
│ prescribed for the purpose of HA prevention or     │ prescribed for the purpose of HA prevention or     │
│ treatment must be stable for at least 4 weeks. The │ treatment. The incidental use of magnesium in      │
│ incidental use of magnesium in multi-vitamins,     │ multi-vitamins, laxatives, etc. is permissible but │
│ laxatives, etc. is permissible but must be         │ must be documented                                 │
│ documented                                         │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hormones (for example, testosterone, estrogen, or  │ Hormones (for example, testosterone, estrogen, or  │
│ progesterone) in any form                          │ progesterone) in any form                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The use of butalbital in any form within 4 weeks   │ The use of butalbital in any form within 4 weeks   │
│ of beginning the Preliminary Screening Period (P1) │ of beginning the Preliminary Screening Period (P1) │
│ through the end of the participant's study         │ through the end of the participant's study         │
│ involvement is exclusionary                        │ involvement is exclusionary                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participants who have been taking trazodone will   │ Participants who have been taking trazodone will   │
│ undergo a 2-week washout period before the         │ undergo a 2-week washout period before the         │
│ Preliminary Screening Period (P1 visit). Combining │ Preliminary Screening Period (P1 visit). Combining │
│ prazosin and trazodone may increase the risk of    │ prazosin and trazodone may increase the risk of    │
│ priapism. We have decided to begin the washout     │ priapism. We have decided to begin the washout     │
│ period before the Preliminary Screening Period in  │ period before the Preliminary Screening Period in  │
│ order to remove any confounding variables while on │ order to remove any confounding variables while on │
│ the headache log and actigraphy                    │ the headache log and actigraphy                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sildenafil (Viagra), tadalafil (Cialis),           │ Sildenafil (Viagra), tadalafil (Cialis),           │
│ vardenafil (Levitra), and avanafil (Stendra) will  │ vardenafil (Levitra), and avanafil (Stendra) will  │
│ not be permitted during the study drug dose        │ not be permitted during the study drug dose        │
│ Titration Period, because of increased risk of     │ Titration Period, because of increased risk of     │
│ hypotension in combination with alpha-1 blockers,  │ hypotension in combination with alpha-1 blockers,  │
│ but will be allowed at half the usual starting     │ but will be allowed at half the usual starting     │
│ dose following the study drug dose Titration       │ dose following the study drug dose Titration       │
│ Period, per VA prescribing guidelines              │ Period, per VA prescribing guidelines              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of supplements containing nitrates and         │ Use of supplements containing nitrates and         │
│ supplements containing stimulants (such as         │ supplements containing stimulants (such as         │
│ ephedra) are exclusionary in the two weeks prior   │ ephedra) are exclusionary in the two weeks prior   │
│ to initial screen (P1) visit and prohibited        │ to initial screen (P1) visit and prohibited        │
│ throughout the study. Participants who take these  │ throughout the study. Participants who take these  │
│ supplements will be asked to discontinue them for  │ supplements will be asked to discontinue them for  │
│ a minimum of two weeks before the Preliminary      │ a minimum of two weeks before the Preliminary      │
│ Screening Period (P1 visit)                        │ Screening Period (P1 visit)                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of prescribed stimulants (such as amphetamine  │ Use of prescribed stimulants (such as amphetamine  │
│ or dextroamphetamine containing medications) is    │ or dextroamphetamine containing medications) is    │
│ exclusionary in the 2 weeks prior to the initial   │ exclusionary in the 2 weeks prior to the initial   │
│ screen (P1) visit and prohibited throughout the    │ screen (P1) visit and prohibited throughout the    │
│ study. Participants who take these medications     │ study. Participants who take these medications     │
│ will be asked to discontinue them for a minimum of │ will be asked to discontinue them for a minimum of │
│ 2 weeks before the Preliminary Screening Period    │ 2 weeks before the Preliminary Screening Period    │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                 │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ History of blast and/or impact head trauma mTBI meeting Defense and Veterans Brain Injury Center    │
│ (DVBIC) mTBI criteria, which define mTBI as an injury to the head causing at least one of the       │
│ following: alteration in consciousness (for up to 24 hours after the injury), loss of consciousness │
│ 0-30 minutes, and/or post-traumatic amnesia up to 1 day post-injury. If available, the Glasgow Coma │
│ Scale score must be 13-15, and head imaging findings (if imaging was performed) must be negative    │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Frequent HAs that started within 3months after a head injury. The HAs either 1) must last 4 or more │
│ hours a day and reach a moderate to severe intensity at any point during the headache, or 2) may be │
│ of any severity or duration if the participant takes a triptan or ergotamine. HAs meeting these     │
│ criteria must have been present on average at least 8 days per 4-week period, starting within 30    │
│ days after head injury and occurring by self-report for at least 3 months prior to the Initial      │
│ Screening Visit. The 4-week HA frequency/severity criteria must be confirmed during the Preliminary │
│ Screening Period                                                                                    │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Diagnosis of a primary or secondary HA disorder other than PTHA                                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Lifetime history of 5 or more migraine or probable migraine headaches pre-dating mTBI               │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Continuous HAs of any kind (i.e., persistent daily HAs with no HA-free period less than 8 hours     │
│ between attacks)                                                                                    │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ The "as-needed" (prn) use of psychoactive and other drugs such as antibiotics is not excluded;      │
│ however, such use must be discussed with a clinician prescriber and documented                      │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ o Mild TBI is defined as an injury to the head causing at least one of the following: alteration in  │
│ consciousness (for up to 24 hours after the injury), loss of consciousness (0-30 minutes), and/or    │
│ post-traumatic amnesia (up to 1 day post-injury). If available, the Glasgow Coma Scale score must be │
│ 13-15, and head imaging findings (if imaging was performed) must be negative                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ HAs meeting these criteria must have been present on average at least 8 days per 4-week period and   │
│ occurring at a stable level by self-report for at least 3 months prior to the Initial Screening      │
│ Visit. The 4-week HA frequency/severity criteria must be confirmed during the Preliminary Screening  │
│ Period                                                                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ A primary non migraine and/or tension-type HA disorder (for example hemicrania continua; cluster)    │
│ that accounts for the majority of current symptoms                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Cannabis: The use of cannabis in any form is not excluded unless its use meets criteria for Cannabis │
│ Use Disorder. All use of cannabis will be documented                                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ History of blast and/or impact head trauma mild traumatic brain injury (mTBI) meeting Defense and    │
│ Veterans Brain Injury Center (DVBIC) mTBI criteria                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ The "as-needed" (prn) use of any non-exclusionary medications is allowed; however, such use must be  │
│ discussed with a clinician prescriber and documented                                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Frequent headaches (HAs) that started within 3 months after a head injury or marked worsening (a     │
│ two-fold or greater increase in frequency and/or severity) of pre-existing headaches within 3 months │
│ of head injury                                                                                       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Medication-and other Treatment-Related Considerations                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Onabotulinum toxin A and nerve block injections for the purpose of HA prevention are permissible if  │
│ the treatment response has been stable during the two most recent treatment cycles                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ HAs either 1) must last 4 or more hours a day and reach a moderate to severe intensity at any point  │
│ during the headache, or 2) may be of any severity or duration if the participant takes a medication  │
│ or other agent in an effort to stop or treat a headache                                              │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛